阿法骨化醇联合钙治疗特发性甲状旁腺功能减退症的疗效与安全性评估
该观察性研究纳入92例接受阿法骨化醇和口服钙治疗的特发性甲状旁腺功能减退症患者,评估其疗效与安全性。常规随访中仅38%患者血钙达标;依从性良好时全部达标,43%可停用口服钙,但高磷血症和高钙尿症在各阶段持续存在。
要点
- 常规随访中仅38%特发性甲旁减患者血钙控制达标
- 依从性良好时43%患者单用阿法骨化醇即可维持血钙达标
- 血钙达标常伴高磷血症和高钙尿症,需监测尿钙和血磷
核心结论
- 阿法骨化醇可有效实现特发性甲状旁腺功能减退症的血钙控制,43%患者可停用口服钙。
- 但最佳血钙控制多伴随高磷血症和高钙尿症。
研究设计与样本
- 三级医疗中心开展的观察性研究,纳入92例接受阿法骨化醇和口服钙治疗的特发性甲状旁腺功能减退症患者。
- 以维持血清总钙8.0至8.5 mg/dL为目标,对控制欠佳者免费供药并频繁随访,序贯滴定口服钙和阿法骨化醇至最低有效剂量。
主要发现
- 常规随访中仅38%患者血钙控制达标。
- 依从性良好时全部患者达到最佳血清钙和1,25-二羟维生素D水平,43%患者可停用口服钙。
- 高磷血症、高钙尿症(尿钙/肌酐比>0.2)和低FEPh在各治疗阶段持续存在。
- 血清钙升至9.9 mg/dL时血磷正常化,但该水平下90%患者出现高钙尿症。
关键数值与推荐
- 目标血清总钙为8.0至8.5 mg/dL。
- 高钙尿症定义为尿钙/肌酐比>0.2。
- 血清钙9.9 mg/dL时血磷正常化,但90%患者出现高钙尿症。
临床怎么用
- 特发性甲旁减患者用阿法骨化醇和钙治疗时应评估依从性,部分患者可尝试停用口服钙。
- 血钙达标后仍需监测血磷和尿钙,警惕高磷血症与高钙尿症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Patients with hypoparathyroidism are treated with vitamin D and calcium. PTH is an emerging option because of its physiological action. It is important to assess the efficacy and shortcomings of conventional therapy. OBJECTIVE: We assessed the efficacy and safety of alfacalcidol in a large cohort of patients with idiopathic hypoparathyroidism (IH) and identified a subset who could be treated without oral calcium. DESIGN AND SETTING: Observational study at tertiary care center. SUBJECTS AND METHODS: We assessed 92 patients with IH who were receiving alfacalcidol and oral calcium to maintain an optimal serum total calcium level of 8.0 to 8.5 mg/dL during routine follow-up. Patients with suboptimal control were provided free medicines and followed up frequently. Oral calcium and alfacalcidol doses were titrated sequentially to determine the minimum doses for optimal calcium control. Serum phosphate level, 1,25-dihydroxyvitamin D, fractional excretion of phosphorus (FEPh), and hypercalciuria (urine calcium-to-creatinine ratio, >0.2) were assessed at each step of titration. RESULTS: Only 38% of patients had optimal calcium control during routine follow-up. With good compliance, all achieved optimal serum calcium and 1,25-dihydroxyvitamin D levels and 43% of patients could stop taking oral calcium. Hyperphosphatemia, hypercalciuria, and low FEPh persisted at all stages of therapy. Serum phosphorus levels normalized when the serum calcium level increased to 9.9 mg/dL, but this level of serum total calcium was associated with hypercalciuria in 90% of patients. CONCLUSION: Alfacalcidol is effective in achieving calcemic control in IH. Calcemic control without oral calcium was achieved in 43% of patients receiving alfacalcidol. However, optimal calcium control was associated with hyperphosphatemia and hypercalciuria in most patients.
引用
- Saha S, Goswami R. Auditing the Efficacy and Safety of Alfacalcidol and Calcium Therapy in Idiopathic Hypoparathyroidism. J Clin Endocrinol Metab. 2019. PMID: 30608544. doi:10.1210/jc.2018-02228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。